TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
31.51
+2.74 (9.52%)
At close: Mar 17, 2026, 4:00 PM EDT
31.43
-0.08 (-0.25%)
After-hours: Mar 17, 2026, 6:49 PM EDT

TG Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
5,0324,6304,6912,5861,7322,722
Market Cap Growth
7.42%-1.30%81.36%49.35%-36.37%-62.78%
Enterprise Value
5,1444,7404,6322,4781,6522,484
Last Close Price
31.5129.8130.1017.0811.8319.00
PE Ratio
11.3810.76200.67189.78-7.17-7.22
Forward PE
23.6820.2945.21---
PEG Ratio
0.13-----
PS Ratio
8.167.5114.2611.07621.81406.90
PB Ratio
6.977.1421.0916.1129.5611.48
P/TBV Ratio
7.857.4321.7015.8027.3410.59
P/FCF Ratio
--185.29-115.64-82.33-9.83-9.19
P/OCF Ratio
--186.89-115.77-82.33-9.83-9.21
EV/Sales Ratio
8.357.6914.0810.61593.01371.30
EV/EBITDA Ratio
41.6938.42110.30118.89-7.58-7.21
EV/EBIT Ratio
41.7138.44110.48120.11-7.56-7.20
EV/FCF Ratio
--189.72-114.20-78.89-9.37-8.39
Debt / Equity Ratio
0.390.391.140.681.390.32
Debt / EBITDA Ratio
2.062.066.045.32-0.38-0.23
Debt / FCF Ratio
-10.15-10.15-6.25-3.53-0.47-0.27
Net Debt / Equity Ratio
0.170.17-0.26-0.66-1.34-0.99
Net Debt / EBITDA Ratio
0.910.91-1.36-5.120.360.68
Net Debt / FCF Ratio
-4.47-4.471.413.400.450.80
Asset Turnover
0.750.750.730.890.010.01
Inventory Turnover
0.850.850.510.71--
Quick Ratio
2.912.914.855.003.044.84
Current Ratio
4.104.106.255.923.165.06
Return on Equity (ROE)
102.75%102.75%12.21%11.57%-151.36%-92.03%
Return on Assets (ROA)
-83.23%-32.53%10.04%8.12%-76.17%-68.59%
Return on Invested Capital (ROIC)
-138.64%-54.18%35.78%99.11%2881.87%3156.08%
Return on Capital Employed (ROCE)
17.66%17.66%10.99%9.91%-96.04%-80.90%
Earnings Yield
8.89%9.29%0.50%0.53%-13.95%-13.84%
FCF Yield
-0.50%-0.54%-0.86%-1.21%-10.17%-10.88%
Buyback Yield / Dilution
1.94%1.94%0.17%-1.85%-0.03%-0.09%
Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q